Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study ; volume:9 ; number:1 ; day:4 ; month:7 ; year:2023 ; pages:1-10 ; date:12.2023
Pilot and feasibility studies ; 9, Heft 1 (4.7.2023), 1-10, 12.2023
- Urheber
-
Hard, Bernadette
DeSilva, Mohan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40814-023-01348-5
- URN
-
urn:nbn:de:101:1-2023093011263550421500
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hard, Bernadette
- DeSilva, Mohan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Physicians’ satisfaction with providing buprenorphine treatment
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Physicians’ satisfaction with providing buprenorphine treatment
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Tom Chamberlain, Regardless
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study